The Latin America, Middle East and Africa Epigenetics Market would witness market growth of 17.8% CAGR during the forecast period (2022-2028).
Numerous illnesses and other health indicators, including malignancies, respiratory diseases, cardiovascular diseases, reproductive problems, autoimmune disorders, and cognitive dysfunction afflictions, may have a direct or indirect link with epigenetic pathways. Heavy metals, pesticides, tobacco smoke, hormones, radiation, viruses, environmental variables, and basic nutrients, all of which contribute to such situations, are on the rise, bolstering the growth of the market.
Growing risk factors and the accompanying increase in cancer cases, higher R&D activities, rising pharmaceutical and biotechnology industries, epigenetics application expanse, and other causes are some of the market's growth catalysts. In addition, massive adoption is being fueled by the development of highly sensitive and selective tests, instrumentation, and a concomitant increase in processing capacity. The development of DNA and RNA modifying enzymes including acetylases, reverse transcriptase, methyltransferases, ligases, and other protein-modifying enzymes has sparked a lot of interest and accelerated the epigenetics market acceptance.
The medical utility of genetic markers for illness prediction and prevention in heart and other muscle cells has been restricted. This is the uncharted area in the field of risk classification, prevention, and treatment, and it has piqued the interest of the cardiovascular research community. Although current enthusiasm for its clinical applications greatly outnumbers available data, the subject of cardiovascular epigenetics is quickly increasing. Epigenetics is interesting as an idea because processes like DNA methylation and histone changes connect the genotype to the environment.
Cancer is a new health problem in Africa that needs to be treated properly if the incidence and fatality rates are to be reduced. According to some estimates, population expansion and aging would result in a 70% increase in new cancer occurrences by 2030. This persistent condition has coexisted in Africa with newly found communicable diseases like Malaria, Ebola, AIDS, and COVID19. Despite the fact that cancer mortality rates have surpassed those of AIDS, TB, and malaria combined, there is still a lack of commitment in Africa to combat cancer. Indeed, the majority of emphasis is focused on communicable diseases, but numerous non-communicable diseases, such as cancer, face similar issues.
The Brazil market dominated the LAMEA Epigenetics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $51.7 Million by 2028. The Argentina market is estimated to grow at a CAGR of 18.4% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 17.4% during (2022 - 2028).
Based on Application, the market is segmented into Oncology and Non-Oncology. Based on Product, the market is segmented into Kits, Reagents, Enzymes, and Instruments. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Epigenetics Market is Predict to reach $2.9 Billion by 2028, at a CAGR of 14.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.
By Application
By Product
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 